Serum Institute seeks market authorization for its Covid vaccination as a booster dose from the drug authority.

The Serum Institute of India (SII) has requested that its COVID-19 vaccine Covovax be authorised for marketing as a booster dose. The vaccine will be offered to anyone aged 18 and older, as well as those who have had two doses of Covishield or Covaxin, according to official sources on Thursday.
On October 17, the director of government and regulatory affairs at SII, Prakash Kumar Singh, submitted a market authorization application for the heterologous booster dose of Covovax to the pharmaceuticals controller of India (DCGI). According to reports, the DCGI’s office posed a few questions, after which Singh provided a response in which he discussed the current predicament caused by a new coronavirus type.
In June, the DCGI approved Covovax for restricted emergency use in children aged seven to eleven. The DCGI had approved Covovax for restricted emergency use in adults on December 28, 2021, and for ages 12 to 17 under certain conditions on March 9.
Covovax is produced by the transfer of technology from Novavax. The European Medicines Agency has authorised it for conditional marketing authorization. The World Health Organization (WHO) awarded an emergency use listing on December 2017, 2020. The US-based vaccine manufacturer Novavax Inc. signed a license deal with the SII in August 2020 for the development and commercialization of their COVID-19 vaccine candidate, NVX-CoV2373, in India and low- and middle-income countries.